A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/18/2002	EP1266022A2 Cell-specific adenovirus vectors comprising an internal ribosome entry site
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266013A2 Heparinase iii and uses thereof
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266009A2 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
12/18/2002	EP1266003A2 Kcnb: a potassium channel protein
12/18/2002	EP1266002A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1266000A1 Chordin-like-2 molecules and uses thereof
12/18/2002	EP1265995A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265985A1 Pancreatic islet cell growth factors
12/18/2002	EP1265927A1 Crystal
12/18/2002	EP1265920A2 Angiogenesis-associated proteins, and nucleic acids encoding the same
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265917A2 Tlp peptides and dna sequences coding the same
12/18/2002	EP1265916A2 Therapeutic anti-cytomegalovirus compounds
12/18/2002	EP1265915A2 Novel compounds
12/18/2002	EP1265914A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265911A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
12/18/2002	EP1265905A1 Il-8 receptor antagonists
12/18/2002	EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265898A2 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY
12/18/2002	EP1265896A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
12/18/2002	EP1265891A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/18/2002	EP1265887A2 Carbocyclic side chain containing metalloprotease inhibitors
12/18/2002	EP1265886A2 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
12/18/2002	EP1265878A1 A process for the preparation of epothiline analogs and intermediates
12/18/2002	EP1265865A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
12/18/2002	EP1265864A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
12/18/2002	EP1265863A1 Heterocyclic side chain containing metalloprotease inhibitors
12/18/2002	EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265854A1 Sponge antitumor compounds
12/18/2002	EP1265848A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
12/18/2002	EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002	EP1265839A1 Compounds active at the glucocorticoid receptor
12/18/2002	EP1265637A2 Compositions and methods for affecting osteogenesis
12/18/2002	EP1265635A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
12/18/2002	EP1265628A1 Use of human not1 and not1a orphan receptors
12/18/2002	EP1265627A2 Methods and compositions for inhibiting angiogenesis
12/18/2002	EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002	EP1265612A1 Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid
12/18/2002	EP1265611A2 Farnesyl protein transferase inhibitor combinations with taxane compounds
12/18/2002	EP1265603A2 Il-8 receptor antagonists
12/18/2002	EP1265596A2 Medical emulsion for lubrication and delivery of drugs
12/18/2002	EP1265595A2 Stabilized ascorbic acid solutions
12/18/2002	EP1265582A2 Colon and colon cancer associated polynucleotides and polypeptides
12/18/2002	EP1086101B1 Beta-carboline compounds
12/18/2002	EP0994729B1 Use of intravenous contrast agents and devices for projection mammography
12/18/2002	EP0989847B1 Anti-tumoral therapy agent
12/18/2002	EP0973801B1 GnRH ANTAGONISTS
12/18/2002	EP0934300B1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/18/2002	EP0930887B1 Cancer immunotherapy using tumor cells combined with mixed lymphocytes
12/18/2002	EP0912584B1 New bis-platinum complexes with polyamine ligands as antitumor agents
12/18/2002	EP0892811B1 Peptides with antiproliferative properties
12/18/2002	EP0873309B1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
12/18/2002	EP0859784B1 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
12/18/2002	EP0778844B1 Functional terpyridine metal complexes, methods for their preparation and oligonucleotide conjugates with terpyridine metal complexes
12/18/2002	EP0769018B1 Helicobacter proteins and vaccines
12/18/2002	EP0760668B1 Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases
12/18/2002	EP0715523B1 Purine nucleoside phosphorylase gene therapy for human malignancy
12/18/2002	EP0662150B1 Maspin, a novel serpin with tumor suppressing activity
12/18/2002	EP0650357B1 Rapamycin derivatives
12/18/2002	EP0641385B1 Development of dna probes and immunological reagents of human tumor associated antigens
12/18/2002	CN1385443A Humanized liver cancer monoantibody, its preparation process and use
12/18/2002	CN1385173A Medicine for treating cancer
12/18/2002	CN1385167A Antimony halide medicine composition for treating leukemia and lymphoma
12/18/2002	CN1385154A Slow-releasing injection type demehylcantharidin for antitumor
12/18/2002	CN1096463C Procss for producing ecteinascidin and intermediate of said process
12/18/2002	CN1096462C 7,12-dioxabenz [a] anthracene compounds, process for preparing them and pharmaceutical compositions containing them
12/18/2002	CN1096448C Farnesyl transferase inhibitors, its preparation and medicine composition thereof
12/18/2002	CN1096263C Lipid complexes and liposomes of highly insoluble platnium complexes
12/17/2002	US6495684 Inhibit human factor xa; treating diseases characterized by thrombotic activity; for example 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine
12/17/2002	US6495677 Nucleoside compounds
12/17/2002	US6495666 Polypeptide composing human chimeric antibody
12/17/2002	US6495662 Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
12/17/2002	US6495600 Method and composition for selectively inhibiting melanoma
12/17/2002	US6495597 N-formyl hydroxylamine derivatives
12/17/2002	US6495594 Biologically active analogs of discodermolide
12/17/2002	US6495585 Method for treating hyperproliferative tissue in a mammal
12/17/2002	US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
12/17/2002	US6495578 Sulfonamide derivatives having oxadiazole rings
12/17/2002	US6495574 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
12/17/2002	US6495571 Administering to the mammal an effective cancer treatment amount of the compound 3,5-dichloro-4,6-diethoxy-2-(trichloromethyl)pyridine or and acid addition salt to treat the cancer
12/17/2002	US6495568 Treatment of tissue ulceration, wound repair and skin diseases
12/17/2002	US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002	US6495564 Such as 3-(6-((4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)-benzaldehyde o-methyl-oxime; inhibiting abnormal cell growth
12/17/2002	US6495560 10,11-dihydro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1 -ethoxy)-5h-dibenzo(a,d)cycloheptene-10-acetic acid; treatment of osteoporosis
12/17/2002	US6495556 Treating leukemia and lymphoma, sunburn and skin cancer
12/17/2002	US6495553 Methods and compositions for overcoming resistance to biologic and chemotherapy
12/17/2002	US6495552 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
12/17/2002	US6495545 1,4-benzodiazepinone derivatives and their use as integrin antagonists
12/17/2002	US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002	US6495543 Treating or preventing melatoninergic disorders
12/17/2002	US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/17/2002	US6495526 Inhibitors of cell-cycle progression and uses related thereto
12/17/2002	US6495525 N-((4-(((2-methylphenylamino)carbonyl)amino)phenyl)acetyl)-l -prolyl-3-methyl)-beta-alanine; very late antigen-4 cell adhesion inhibitor; inflammation and immune reactions

1 ... 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 ... 2211